| Previous Close | 14.25 |
| Open | 14.30 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 14.12 - 14.77 |
| 52 Week Range | 8.69 - 17.20 |
| Volume | 329,024 |
| Avg. Volume | 468,812 |
| Market Cap | 762.07M |
| Beta | 2.10 |
| PE Ratio (TTM) | -41.89 |
| EPS (TTM) | -0.34 |
| Earnings Date | Oct 25, 2017 - Oct 30, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.86 |
- GlobeNewswire•3 days ago
Cytokinetics Announces Dosing of First Patient in Japan in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2017-- Cytokinetics, Incorporated today announced that the first patient has been dosed in Japan in GALACTIC-HF, the Phase 3 cardiovascular outcomes clinical trial ...
- GlobeNewswire•4 days ago
Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA 21st Annual Scientific Meeting
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2017-- Cytokinetics, Incorporated today announced that additional results from COSMIC-HF, a Phase 2 trial evaluating omecamtiv mecarbil in patients with chronic heart ...
- Zacks•7 days ago
Options Traders Expect Huge Moves in Cytokinetics (CYTK) Stock
Investors in Cytokinetics (CYTK) need to pay close attention to the stock based on moves in the options market lately.
